- AB-FUBINACA
- AMB-FUBINACA
Longworth, M; Banister, SD; Mack, JBC; Glass, M; Connor, M; Kassiou, M. The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicol., 1 Jul 2016, 34 (2), 286–303. 1.3 MB. https://doi.org/10.1007/s11419-016-0316-y #4
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
Smolianitski-Fabian, E; Cohen, E; Dronova, M; Voloshenko-Rossin, A; Lev, O. Discrimination between closely related synthetic cannabinoids by GC-Cold-EI-MS. Drug Test. Anal., 1 Mar 2018, 10 (3), 474-487. 1.3 MB. https://doi.org/10.1002/dta.2247
Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst, 25 Jan 2016, 141 (3), 902–909. 1.3 MB. https://doi.org/10.1039/c5an02326b
Dunne, SJ; Rosengren-Holmberg, JP. Quantification of synthetic cannabinoids in herbal smoking blends using NMR. Drug Test. Anal., 1 May 2017, 9 (5), 734-743. 988 kB. https://doi.org/10.1002/dta.2032
Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Drug Test. Anal., 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #AB FUBINACA LC,MS
Zawilska, JB; Andrzejczak, D. Next generation of novel psychoactive substances on the horizon – A complex problem to face. Drug Alcohol Depend., 1 Jan 2015, 157, 1-17. 3.0 MB. https://doi.org/10.1016/j.drugalcdep.2015.09.030
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #72
Vajs, V; Djordjević, I; Vujisić, L; Milosavljević, SM. NMR spectroscopy in the analysis of illegal drugs. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 177–197. 5.4 MB.
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB.
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #8. AB-FUBINACA
Davidson, C; Opacka-Juffry, J; Arevalo-Martin, A; Garcia-Ovejero, D; Molina-Holgado, E; Molina-Holgado, F. Spicing up pharmacology: A review of synthetic cannabinoids from structure to adverse events. In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 135–168. 458 kB. https://doi.org/10.1016/bs.apha.2017.05.001 #AB-FUBINACA
Noble, C; Cannaert, A; Linnet, K; Stove, CP. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. Drug Test. Anal., 2 Oct 2018, 11 (3), 501-511. 935 kB. https://doi.org/10.1002/dta.2517 #8
EMCDDA. Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Mar 2017. 765 kB. #AB-FUBINACA IR,UV
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #60
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #46
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #AB-FUBINACA
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #AB-FUBINACA
Banister, SD; Kevin, RC; Martin, L; Adams, A; Macdonald, C; Manning, JJ; Boyd, R; Cunningham, M; Stevens, MY; McGregor, IS; Glass, M; Connor, M; Gerona, RR. The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug Test. Anal., 5 Mar 2019, 11 (7), 976-989. 1.6 MB. https://doi.org/10.1002/dta.2583 #2 MS,NMR
Patel, M; Manning, JJ; Finlay, DB; Javitch, JA; Banister, SD; Grimsey, NL; Glass, M. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochem. Pharmacol., 1 May 2020, 175 113871. 1.9 MB. https://doi.org/10.1016/j.bcp.2020.113871 #AB-FUBINACA
Dimmito; Stefanucci; Pieretti; Minosi; Dvorácskó; Tömböly; Zengin; Mollica. Discovery of orexant and anorexant agents with indazole scaffold endowed with peripheral antiedema activity. Biomolecules, 16 Sep 2019, 9 (9), 492. 4.3 MB. https://doi.org/10.3390/biom9090492 #AB-FUBINACA LC,MS,NMR
Kikura-Hanajiri, R. New designer drugs in japan. In Neuropathology of Drug Addictions and Substance Misuse; Preedy, VR, Ed., Academic Press, 1 Jan 2016; pp 1055–1065. 682 kB. https://doi.org/10.1016/B978-0-12-800212-4.00097-2 #AB-FUBINACA
Åstrand, A; Guerrieri, D; Vikingsson, S; Kronstrand, R; Green, H. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Sci. Int., 1 Dec 2020, 317, 110553. 1.7 MB. https://doi.org/10.1016/j.forsciint.2020.110553 #AB-FUBINACA
Qian, Z; Hua, Z; Liu, C; Jia, W. Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances. Forensic Toxicol., 1 Jan 2016, 34 (1), 133–143. 589 kB. https://doi.org/10.1007/s11419-015-0297-2 #5 GC,MS,NMR
Worob, A; Wenthur, C. DARK classics in chemical neuroscience: Synthetic cannabinoids (Spice/K2). ACS Chem. Neurosci., 2 Dec 2020, 11 (23), 3881–3892. 1.5 MB. https://doi.org/10.1021/acschemneuro.9b00586 #23
Wagmann, L; Stiller, RG; Fischmann, S; Westphal, F; Meyer, MR. Going deeper into the toxicokinetics of synthetic cannabinoids: In vitro contribution of human carboxylesterases. Arch. Toxicol., 1 Nov 2022, 96 (10), 2755–2766. 1.6 MB. https://doi.org/10.1007/s00204-022-03332-z #AB-FUBINACA